Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 or older who have been diagnosed with prostate cancer (confirmed through a tissue sample) and have already had their prostate surgically removed, with a PSA blood test result of 0.1 ng/mL or higher
- At least 6 months must have passed between the prostate removal surgery and the planned start date for radiation treatment
- A general health and functioning score (called KPS) of 70 or above, meaning the person is reasonably able to carry out normal daily activities (confirm with trial site)
- People who have uncertain or borderline findings on pelvic lymph nodes in scans may still be eligible, as long as the lymph nodes are no larger than 1.5 cm in their shorter measurement; if there are uncertain signs of cancer spread outside the pelvis, a biopsy confirming it is not cancer would be required
- Ability to complete a prostate-related quality of life questionnaire called the EPIC-26
- Tissue from the prostate removal surgery must be available for review by the Michigan Medicine Pathology department
- Ability to understand and willingness to sign a written consent form to participate
Who may not be able to join:
- People who have previously received radiation therapy to the pelvic area
- People with a history of moderate to severe, or currently active, Crohn's disease or ulcerative colitis (inflammatory bowel conditions)
- People who have had a narrowing or blockage of the bladder neck or urethra (the tube that carries urine out of the body)
- People who have evidence that cancer has spread to distant parts of the body, or to lymph nodes beyond a certain point in the pelvis
- People who started certain hormone-reducing therapies (known as LHRH or GnRH agonists or antagonists) more than 6 months before enrolling, or who have received other types of hormone or anti-androgen treatments for their prostate cancer
- People who have had another serious (invasive) cancer within the past 3 years, except for certain treated skin cancers (squamous cell or basal cell carcinoma)
- People with any other health condition that the trial doctor considers would make participation unsafe or unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: William Jackson, M.D., University of Michigan Rogel Cancer Center
Phone: 1-800-865-1125
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in patient reported GI and GU quality of life (QOL) at 2-years post-treatment from baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.